A Phase 2 Study of PCM-075 (Onvansertib) in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Phase: PHASE2
Conditions: Metastatic Castration-Resistant Prostate Cancer
Sponsor: Cardiff Oncology

Protocol Number: TROV-053 
Official Title: A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and 
Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer 
NCT Number: NCT03414034 
Document Date: 16 Nov 2020